WO2011093815A3 - Compositions pharmaceutiques comprenant du formotérol et du mométasone - Google Patents

Compositions pharmaceutiques comprenant du formotérol et du mométasone Download PDF

Info

Publication number
WO2011093815A3
WO2011093815A3 PCT/TR2011/000017 TR2011000017W WO2011093815A3 WO 2011093815 A3 WO2011093815 A3 WO 2011093815A3 TR 2011000017 W TR2011000017 W TR 2011000017W WO 2011093815 A3 WO2011093815 A3 WO 2011093815A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
formoterol
mometasone
capsule
pharmaceutically acceptable
Prior art date
Application number
PCT/TR2011/000017
Other languages
English (en)
Other versions
WO2011093815A2 (fr
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2010/00684A external-priority patent/TR201000684A2/xx
Priority claimed from TR2010/00727A external-priority patent/TR201000727A2/xx
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Priority to EP11706962A priority Critical patent/EP2533765A2/fr
Publication of WO2011093815A2 publication Critical patent/WO2011093815A2/fr
Publication of WO2011093815A3 publication Critical patent/WO2011093815A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques sous forme de poudre sèche comprenant du formotérol et du furoate de mométasone et/ou leurs dérivés pharmaceutiquement acceptables utilisés comme principes actifs. Elle concerne également des formes en capsules ou plaquettes alvéolaires contenant ces compositions pharmaceutiques destinées à être utilisées dans le traitement de maladies des voies respiratoires.
PCT/TR2011/000017 2010-01-29 2011-01-28 Compositions pharmaceutiques comprenant du formotérol et du mométasone WO2011093815A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11706962A EP2533765A2 (fr) 2010-01-29 2011-01-28 Compositions pharmaceutiques comprenant du formotérol et du mométasone

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
TR2010/00684A TR201000684A2 (tr) 2010-01-29 2010-01-29 Formoterol ve mometazon içeren farmasötik bileşimler
TR2010/00684 2010-01-29
TR2010/00727A TR201000727A2 (tr) 2010-02-02 2010-02-02 Formoterol ve mometazon içeren farmasötik bileşimler.
TR2010/00727 2010-02-02

Publications (2)

Publication Number Publication Date
WO2011093815A2 WO2011093815A2 (fr) 2011-08-04
WO2011093815A3 true WO2011093815A3 (fr) 2011-10-20

Family

ID=44169040

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000017 WO2011093815A2 (fr) 2010-01-29 2011-01-28 Compositions pharmaceutiques comprenant du formotérol et du mométasone

Country Status (2)

Country Link
EP (1) EP2533765A2 (fr)
WO (1) WO2011093815A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013109211A1 (fr) * 2012-01-16 2013-07-25 Mahmut Bilgic Formulations en poudre sèche comprenant du r-formotérol utilisé comme agent actif
WO2013109207A1 (fr) * 2012-01-16 2013-07-25 Mahmut Bilgic Formulations de poudre sèche comprenant de la mométasone
WO2013109208A1 (fr) * 2012-01-16 2013-07-25 Mahmut Bilgic Formulations comprenant du formotérol utilisé comme agent actif
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
US20150165037A1 (en) * 2012-07-05 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising corticosteroid and sorbitol

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000051591A1 (fr) * 1999-03-03 2000-09-08 Novartis Ag Combinaisons de formoterol et de furoate de mometasone destinees a l'asthme
WO2000053187A1 (fr) * 1999-03-09 2000-09-14 Astrazeneca Ab Nouvelle combinaison de formoterol et de mometasone dans une composition pharmaceutique permettant de traiter des troubles respiratoires tels que l'asthme, les rhinites et la broncho-pneumopathie chronique obstructive
WO2001078744A1 (fr) * 2000-04-18 2001-10-25 Glaxo Group Limited Produits composes a usage medical renfermant du formoterol et de la mometasone
EP1176162A2 (fr) * 2000-06-22 2002-01-30 Mitsubishi Polyester Film Corporation Film de polyester orienté biaxialement
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
WO2003078429A1 (fr) * 2002-03-20 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Micronisat cristallin de bromure de tiotropium
WO2003086350A1 (fr) * 2002-04-05 2003-10-23 3M Innovative Properties Company Formulations d'aerosols a base de formoterol et de mometasone
WO2005044187A2 (fr) * 2003-10-28 2005-05-19 Glaxo Group Limited Preparations pharmaceutiques inhalables employant de l'anhydrate de lactose, et methodes d'administration desdites preparations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
CY1359A (en) 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000051591A1 (fr) * 1999-03-03 2000-09-08 Novartis Ag Combinaisons de formoterol et de furoate de mometasone destinees a l'asthme
WO2000053187A1 (fr) * 1999-03-09 2000-09-14 Astrazeneca Ab Nouvelle combinaison de formoterol et de mometasone dans une composition pharmaceutique permettant de traiter des troubles respiratoires tels que l'asthme, les rhinites et la broncho-pneumopathie chronique obstructive
WO2001078744A1 (fr) * 2000-04-18 2001-10-25 Glaxo Group Limited Produits composes a usage medical renfermant du formoterol et de la mometasone
EP1176162A2 (fr) * 2000-06-22 2002-01-30 Mitsubishi Polyester Film Corporation Film de polyester orienté biaxialement
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
WO2003078429A1 (fr) * 2002-03-20 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Micronisat cristallin de bromure de tiotropium
WO2003086350A1 (fr) * 2002-04-05 2003-10-23 3M Innovative Properties Company Formulations d'aerosols a base de formoterol et de mometasone
WO2005044187A2 (fr) * 2003-10-28 2005-05-19 Glaxo Group Limited Preparations pharmaceutiques inhalables employant de l'anhydrate de lactose, et methodes d'administration desdites preparations

Also Published As

Publication number Publication date
EP2533765A2 (fr) 2012-12-19
WO2011093815A2 (fr) 2011-08-04

Similar Documents

Publication Publication Date Title
WO2012016889A3 (fr) Formulation de poudre sèche comprenant un inhibiteur de phosphodiestérase
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
IL216741A (en) History of imidazolidine-2-van 1,3-imaging modalities as 17-cyp inhibitors, pharmaceutical preparations containing them, and their use in the preparation of drugs for the treatment of diseases
IL223795A (en) History of Tetrahydro-Pyrido-Pyrimidine
JP2010132695A5 (fr)
IL213019A (en) Derivatives 1-Azo-3-Terroyl-Azoline, Pharmaceutical Preparations Containing and Using Them
TR201000680A2 (tr) Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler
WO2013183062A3 (fr) Formulations d'ibuprofène de goût agréable
WO2012098562A3 (fr) Compositions liquides pour administration par voie orale de sels de lanthane
IL232764A (en) Fluoromethyl6,5 - Dihydro - 4 H - [3,1] Oxazines, Pharmaceuticals Containing Them and Their Use in the Preparation of Medicines to Treat Alzheimer's Disease
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
WO2014016548A3 (fr) Composition pharmaceutique
WO2011093815A3 (fr) Compositions pharmaceutiques comprenant du formotérol et du mométasone
TR201000733A2 (tr) Flutikazon, tiotropyum ve sodyum kromoglikat içeren farmasötik bileşimler.
WO2011093818A3 (fr) Compositions pharmaceutiques comprenant du salmétérol et du fluticasone
TR201000681A2 (tr) İnhalasyon yoluyla alınan kuru toz formülasyonları.
EA201170117A1 (ru) Противоаллергические биополимеры морского происхождения
WO2012047182A3 (fr) Dispositif d'inhalation de poudre sèche en doses uniques
MX2015015132A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
IL213671A (en) Pharmaceutical preparations containing alglitazar, a process for their preparation and use for the preparation of medicines
WO2011101734A3 (fr) Poudre à goût masqué pour compositions en suspension de méthylprednisolone
WO2011093811A3 (fr) Préparations pharmaceutiques comprenant du formotérol et du fluticasone
IL217519A (en) Derivatives of tazarotene, pharmaceutical preparations containing them and their use in the preparation of medicines for the treatment of skin diseases
WO2011093814A3 (fr) Compositions pharmaceutiques combinées comprenant du formotérol et du ciclésonide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11706962

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2011706962

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011706962

Country of ref document: EP